News
-
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy
Xlife Sciences AG announces strategic collaboration between Firstgene Life Sciences and Hovione in the field of Gene Therapy for Hepatocellular carcinoma treatment, expanding into gene therapy market -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report. Key parameters include rNPV, cost of capital, and development risks -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence
Xlife Sciences AG publishes 2024 Annual Report highlighting strategic partnerships, technological milestones, and dual listing plans on SIX and LSE to enhance international market presence -